Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Variational AI Secures $US3.5 Million in Seed Funding to Apply State-of-the-Art AI Platform to Generate Novel Small Molecule Therapeutics for Drug Development

Variational AI

Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecules, today announced that it has raised $US3.5 million ($CDN4.3 million) in seed funding. The investment round was led by Flying Fish Ventures, Alliance of Angels and A&E Investments, with participation from Lip-Bu Tan and Amarjit Gill, Silicon Valley entrepreneurs, investors and advisors. Variational AI’s Enki algorithm learns from a training set of molecules screened against drug targets from both experimental and computational sources and then generates novel molecular structures with multiple pre-defined parameters/properties optimized to avoid common causes of drug attrition. This optimization is performed in parallel and can deliver results in months versus years and requires significantly less data than competing AI offerings. “The pandemic has demonstrated the importance of accelerating drug discovery and reducing the cost and risk to developing therapeutics,” said Frank Chang managing partner, Flying Fish. “We are thrilled to invest in Variational AI’s machine learning approach to discovering new molecules, which has the potential to dramatically impact the biopharma industry.” The seed funding will enable Variational AI to accelerate existing discovery programs for COVID-19, cancer and other disease areas. The company will also utilize the new capital to hire additional leaders in medicinal chemistry, cheminformatics, and machine learning, and recruit a Scientific Advisory Board. “The Variational AI team is excited to welcome our investors in sharing our vision for redefining the economics of drug development,” said Handol Kim, co-founder and CEO, Variational AI. “We look forward to accelerating our current programs and identifying new drug targets that Enki is uniquely suited to tackle to rapidly address unmet medical needs.” About Variational AI Variational AI uses state-of-the-art machine learning in a data-efficient method to rapidly generate novel and diverse compounds that are optimized for multiple properties to avoid the most common causes of drug attrition and increase clinical probability of success. Variational AI works with leading biopharmaceutical partners and is developing its own internal pipeline. To learn more, visit https://variational.ai. Contact Details Sage Morander +1 401-490-9700 variationalai@svmpr.com Company Website https://variational.ai/

November 17, 2021 10:15 AM Eastern Standard Time

ATAP ACTION NETWORK PHYSICIANS & PATIENT ADVOCATES MEET WITH CONGRESSIONAL OFFICES

Alliance for Transparent & Affordable Prescriptions

Today, physician and patient advocates on behalf of the Alliance for Transparent and Affordable Prescriptions (ATAP) Action Network (AN) will meet virtually with congressional lawmakers’ offices as part of its 2021 Capitol Hill Day. In these meetings, ATAP member organizations are advocating for lowering prescription drug prices for their patients by bringing accountability to the pharmacy benefit manager (PBM) industry. ATAP is an active advocate for patients in federal and state battles to amplify the voices of patients and physicians – especially as it relates to exposing PBM abuses and the impact on access to therapies (medications) needed for the treatment of patients. In the meetings today, ATAP AN will speak to congressional offices about three pieces of legislation, including: the PBM Accountability Study Act (H.R. 1829/S. 298), the Drug Price Transparency Act (S. 1523), and the Prescription Pricing for the People Act (S. 1388). “We are proud to bring policymakers the voices of patients and providers, two groups grossly underrepresented in the drug pricing debate’” said Dr. Robert Levin, the President of ATAP. “These voices from our members, combined with supporting advocacy organizations, and individuals fearing drug cost affordability, will surely inspire national leaders to take action to fix problems created by the PBM industry.” ATAP AN will meet with congressional member offices from Florida, Wisconsin, New York, Virginia, North Carolina, Missouri, Maryland, and California. Michael Schweitz, President of ATAP Action Network and Member of the Florida Society of Rheumatology, stated, “Officials in Washington understand that our members, those on the front lines of medical care, offer a valuable perspective. We see the struggles and confusion that patients are put through by this completely unnecessary middleman industry. We appreciate to opportunity to share these experiences and help more legislators see the light – and shine it on the PBMs.” Several ATAP member organizations are participating in meetings including, the American College of Rheumatology, the Coalition of State Rheumatology Organizations, Lupus and Allied Diseases Association, Inc., and many others. Kathleen A. Arntsen President & CEO of Lupus and Allied Diseases Association, (an ATAP member organization) stated, "As a patient-led organization representing those facing serious health conditions, we have direct experience with the frustration in struggling to access affordable and appropriate treatments due to PBM interference. We are thrilled to have the opportunity to share this information with elected officials and are hopeful that they will stand with patients and support fair drug pricing legislation that holds the PBM industry accountable." “PBMs generate significant profits while patients struggle to afford the cost of care,” said Steven Newmark, Director of Policy at the Global Healthy Living Foundation (an ATAP member organization). “We will show elected officials and policymakers what is really happening in exam rooms, and the stress patients experience due to PBM interference. There is a better way.” Updates from the meetings will be shared at https://atapadvocates.com/ and on Twitter with the hashtag, #ATAPHillDay21. About ATAP ATAP was created in 2017 with a mission to address prescription drugs costs and patient access to affordable treatment by regulating PBM practices and reforming the drug industry through educational outreach and grassroots advocacy initiatives at both the state and federal levels. Driven by the reality that many patients struggle to afford their medications, the physician and patient advocacy organizations joined to shine a light on the abusive practices of PBMs. ### To schedule an interview with an ATAP spokesperson please contact Dan Rene of kglobal at 202-329-8357. Please visit http://www.atapadvocates.com ATAP's mission is to address prescription drugs costs and patient access to affordable treatment by regulating PBM practices and reforming the drug industry through educational outreach and grassroots advocacy initiatives at both the state and federal level. Contact Details Dan Rene +1 202-329-8357 daniel.rene@kglobal.com Company Website http://www.atapadvocates.com

November 16, 2021 10:58 AM Eastern Standard Time

AppYea takes steps for Future Growth

Appyea

Provides the following letter to its shareholders from its Chairman Boris Molchadsky: "I am pleased with the progress AppYea/SleepX has been making this year. As part of the long terms objective, AppYea Inc. (OTCPINK: APYP) took the initial step to advance the prospects of the Company. As disclosed in our quarterly report yesterday to the OTC for the recently completed fiscal quarter, the reverse stock split, for which we are awaiting FINRA approval, is a proactive measure that we believe will better position us for success, and ultimately generate value for all of the Company’s stockholders. The ultimate aim is to raise our stock’s visibility within the investment community by improving long-term liquidity and creating a trading environment attractive to institutional investors in the hopes of broadening our shareholders. We are confident of the prospects of the anticipated commercialization of the SleepX DreamIT X3 in 2022". Mr. Molchadsky continued: “In conjunction with the corporate actions, AppYea has secured funding sources who we believe will asist the Company to restructure prior highly dilutive debt and providing the necessary capital to enable the Company to move forward on several fronts, including: 1. Closing of the merger between AppYea and SleepX—we are awaiting the required necessary regulatory approvals. 2. Completion of development and commencement of manufacturing the first product for snoring treatment. SleepX intends to start a pilot in December with a leading hardware manufacturer after withstanding the Company's endurance tests. 3. Preparation for starting clinical trials of the product for the treatment of Sleep Apnea. 4. Locating and acquiring synergetic technologies and broadening products variety in the sleeping and respiration field. Looking ahead, the primary focus of the Company is to ensure the long-term success of the Company by acting in the best interest of all of our shareholders. Thank you for your continued support and patience”. Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

November 16, 2021 09:09 AM Eastern Standard Time

Image

Connecticut chooses BioTrack as the state's cannabis seed-to-sale tracking software

Forian

Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, announced that Connecticut has chosen BioTrack as the track and trace system for the state’s Department of Consumer Protection Drug Control Division. The state plans to use the BioTrack inventory tracking system to monitor the movement of cannabis products in the state’s medical and adult-use cannabis markets, while providing a real-time inventory of cannabis products available in the state and preventing unlawful diversion of products. The BioTrack software, commonly referred to as seed-to-sale tracking, will track cannabis from when it is first planted as a seed to the point of sale to the consumer. All licensed medical marijuana and adult-use cannabis establishments will be required to participate in the tracking system and log the movement of cannabis as it is grown, manufactured into other products, packaged, tested, and sold to qualifying patients or consumers. BioTrack’s state traceability system will also help recall cannabis plants and products deemed as unsafe/adulterated, and prevent adulterated and regulated materials from reaching the black market. “Connecticut has shown their desire to be at the forefront of cannabis by looking for best-in-class software solutions. We are very excited to work with the state to develop new technologies to support their cannabis-related initiatives,” said Moe Afaneh, VP of BioTrack. BioTrack’s point-of-sale software is used by customers in 38 states and 10 countries, while 10 state governments, including Connecticut, currently use BioTrack's patient portal and traceability system. About Forian Forian Inc. provides a unique suite of SaaS solutions, data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators and regulators. For more information, please visit the Company's website at www.forian.com. Cautionary Statements Regarding Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond the control of Forian, and are not guarantees of future results, such as statements about the anticipated benefits of the business combination transaction involving Forian, Medical Outcomes Research Analytics, LLC and Helix Technologies, Inc., future financial and operating results, company strategy and intended product offerings and market positioning. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Forian's business, operations, strategy and goals; Forian's ability to execute on its strategy; the timing of the introduction of new product offerings; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Forian's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 31, 2021, and elsewhere in Forian's filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof, and Forian undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. ABOUT FORIAN Forian provides a unique suite of SaaS solutions, data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators and regulators. For more information, please visit the Company's website at www.forian.com. Contact Details Forian Investors ir@forian.com Company Website https://forian.com/

November 15, 2021 02:43 PM Eastern Standard Time

POCONO ORGANICS INTRODUCES NEW CBD GOURMET GUM DROP LINE

Pocono Organics

Pocono Organics’ CBD product line continues to grow as the woman-owned company introduced two new flavorful gourmet attractions, Lemon Chamomile and Vanilla Lavender CBD Gum Drops today. From hemp growing in the nutrient rich fields; transformed into new life as gourmet gum drops formulated by their scientists and Chopped Champion Chef, the pair puts Pocono Organics on the map with the number one form of CBD consumption. “Growing the first and only Regenerative Organic Certified (ROC) hemp in the world and being the largest ROC farm in the U.S.; we tend to set the bar kind of high for our CBD team to excel in creating a premium, wellness product line dedicated to providing convenience and taste-appeal,” smiles Ashley Walsh, Pocono Organics Founder/President. Formulated in-house, each Gourmet Gum Drop tin includes 25 servings and fits right in with Pocono Organics’ small batch, artisanal CBD product line featuring Bath Bombs, Nano-Particle Tincture, Hemp Extract Tincture, Creams, Salve Sticks, and Lip Balms. There’s even a pet-friendly Furry Friends Tincture! Learn more Pocono Organics CBD facts and focus on the future, including its water-soluble nano-particle technology, at PoconoOrganics.com/cbd. Pocono Organics – Inspiring People. Healing the Earth. 1015 Long Pond Road, Long Pond, PA – PoconoOrganics.com About Pocono Organics Pocono Organics is a health and wellness organization with a mission to inspire people and heal the earth. The Global Center for Research, Education, and Innovation grows the world’s first and only Regenerative Organic Certified (ROC) hemp and is one of the largest ROC farms in North America. Located in Long Pond, Pennsylvania, Pocono Organics has more than 380 acres of farmland and, at full build out, will have 120,000 square feet of greenhouse. Pocono Organics has a strategic partnership with Rodale Institute, the global leaders in Regenerative Organic Agriculture science and research and is their largest research satellite facility. Awarded the 2019 Environmental Innovator of the Year by the Green Sports Alliance, sustainability is a hallmark of Pocono Organics. The farm draws power from a 3MW, 25-acre solar farm and reclaims rainwater from 70,000 square feet of roofs for irrigation. Pocono Organics also serves the local community through its Clean Food, Dirty Hands school education program and veterans in transition through a Veteran Farmer Training Program. In addition, the property includes an organic farmer’s market and café featuring a Chopped Champion Chef, and with a 56-room adjoining hotel, is an agritourism destination, and host location for annual festivals. Please visit www.PoconoOrganics.com to learn more about Pocono Organics’ mission and work. Contact Details Pocono Organics Jeanine Hofbauer, Corporate Director of Marketing & Communications +1 570-517-1792 Jeanine@PoconoOrganics.com Company Website https://www.poconoorganics.com/

November 15, 2021 02:00 PM Eastern Standard Time

Image

EXCHANGE LISTING, LLC ADVISES HEARTBEAM INC. AND SECURES NASDAQ LISTING

Exchange Listing

Exchange Listing, LLC has finalized the Nasdaq Capital Markets listing for its client, Heartbeam Inc. (“ HeartBeam ” or the “Company”) (Nasdaq: BEAT and BEATW) on November 11 2021. The emerging digital healthcare company’s common stock began trading on the Nasdaq exchange under the symbols BEAT and BEATW, respectively. Concurrent with the NASDAQ listing, HeartBeam announced the pricing of its underwritten initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $6.00 The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date. All units are being offered by HeartBeam, Inc. In addition, HeartBeam has granted the underwriters a 30-day option to purchase an additional 412,500 shares of its common stock and/or warrants to purchase up to an additional 412,500 of its common stock, at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to HeartBeam from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $16.5 million. The Benchmark Company acted as the sole book-running managers for the offering. The Company, based in Santa Clara, California is a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, “Working with Exchange Listing as IPO counsel put us in a winning position,” commented Branislav Vajdic, CEO, HeartBeam. “Their exemplary team put us in contact with a best in class investment banker and legal team. We are thrilled to now be listed on the Nasdaq Capital Markets.” “When we met the HeartBeam management team, and reviewed their innovative digital healthcare products, we became incredibly enthusiastic about their market potential,” explains Peter Goldstein, Chief Executive Officer of Exchange Listing. “ HeartBeam’s medical grade heart attack detection technology is a game changer, allowing patients to determine if they are having a life threatening medical event. In concert with HeartBeam’s management and bankers, the Company now has a listing on Nasdaq Capital Markets.” Exchange Listing provides companies with cost-effective and efficient direct access to one-stop solutions in the strategic planning and implementation of listing and uplisting on senior exchanges such as the Nasdaq or NYSE. Focusing on company-specific structuring to meet listing requirements, Exchange Listing serves as the primary point of contact with the exchange, investment bankers and lawyers throughout the listing process. With extensive experience in investment banking, securities law, corporate governance and business management, Exchange Listing and its strategic partners facilitate clients' listing and capital markets objectives. About Exchange Listing Exchange Listing provides growth companies with direct access to a one-stop solution in the strategic planning and implementation of listing on a senior exchange such as NASDAQ or NYSE in a cost effective and efficient process. We assist clients in going public whether through an initial public offering, listing from another marketplace, merger or direct offering. We serve as the primary point of contact with the exchange, investment bankers, lawyers and other service providers. Our founders, strategic partners and advisors are entrepreneurs with backgrounds in investment banking, securities law, corporate governance and business management and have served as officers and directors of public and private companies. We pride ourselves in taking a hands-on role with our clients throughout the listing process. For more information, please visit: www.exchangelistingllc.com or contact info@exchangelistingllc.com. Contact Details Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://exchangelistingllc.com/

November 15, 2021 01:17 PM Eastern Standard Time

Doseology Set to Trade CSE: MOOD

Doseology Sciences Inc.

Doseology Sciences Inc. (CSE: MOOD ) (“ Doseology ” or the “ Company ”) is pleased to announce that its shares will begin trading on the CSE today and has retained Hybrid Financial Ltd. (“ Hybrid ”) to provide marketing and call centre services to the Company. Hybrid has agreed to comply with all applicable securities laws and the policies of the Canadian Securities Exchange (the “ CSE ”) in providing their services. Hybrid has been engaged by the Company for an initial period of six (6) months starting from November 15, 2021 (the “ Initial Term ”) and shall be renewed for an additional six (6) months thereafter, unless terminated by the Company in accordance with the Agreement. Hybrid will be paid a monthly fee of $22,500 plus applicable taxes, during the Initial Term. Daniel Vice, CEO and Director commented, “We look forward to Hybrid amplifying market awareness to the Doseology brand and broadening the Company’s reach within the investment community”. No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board of Directors Doseology Sciences Inc. Daniel Vice Chief Executive Officer and Director About Doseology Sciences Inc. Doseology is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health. About Hybrid Financial Ltd. Hybrid is a sales and distribution company that actively connects issuers to the investment community across North America. Using a data driven approach, Hybrid provides its clients with comprehensive coverage of both American and Canadian markets, Hybrid Financial offices in Toronto, and Montreal. FOR FURTHER INFORMATION CONTACT: Investor Relations Email: investor@doseology.com Telephone: 236-349-0064 Website: www.doseology.com Forward Looking Statements This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Contact Details Investor Relations +1 236-349-0064 investor@doseology.com

November 15, 2021 08:00 AM Eastern Standard Time

Customer Experience and Customer Engagement Market to Surpass $100 Billion in Annual Worldwide Revenue by 2026, According to Dash Research

Dash Network

Customer experience (CX) and customer engagement (CE) initiatives continue to be a major priority for organizations around the world, especially in light of the significant changes and disruptions to customer relationships that emerged as a result of the COVID-19 pandemic. According to a new report from Dash Research, this level of focus is leading to brisk growth in the market for CX/CE technology platforms. “While CX improvements are largely driven by organizational change management, software is increasingly being used to support these initiatives by managing and making available the plethora of customer data that is captured and aggregated from a variety of sources,” says principal analyst Keith Kirkpatrick. He adds that some of the key drivers of market growth include pandemic-related shutdowns and reopening, increased focus on omnichannel customer interaction capabilities, the rise of customer centricity, and the elimination of functional silos within organizations. Dash Research forecasts that global CX/CE revenue will increase from $63.6 billion in 2021 to $100.3 billion by 2026. The market size experienced a 13.5% decline between 2019 and 2020 due to economic effects of the COVID-19 pandemic, but spending has recovered in 2021 and is projected to reach 2019 levels again by the end of 2022. The market intelligence firm forecasts that the top 5 industries in terms of CX/CE spending between 2021 and 2026 will be as follows: Telecommunications Healthcare Financial Services & Insurance Retail Government/Public Sector Dash Research’s report, “CX Market Forecasts”, includes a detailed market sizing and forecast model that focuses on the business-to-business (B2B) and business-to-consumer (B2C) software and services opportunity related to CX and CE. The forecast is split into a variety of segments, based on the world region in which the solution is used, the offering itself, functional area, and industry. The impact of the COVID-19 pandemic, the market drivers and barriers, and insights into four industries that are driving the market spending are discussed in the report, along with recommendations for both end users and vendors. An Executive Summary of the report is available for free download on the firm’s website. Dash Research, the market intelligence arm of Dash Network, provides in-depth research and insights on the worldwide CX market including a comprehensive assessment of technology solutions, business issues, market drivers, and end-user dynamics across industry sectors. Dash Research’s global market coverage combines qualitative and quantitative research methodologies to provide a complete view of emerging business opportunities surrounding contact center technologies, customer data & analytics, customer data platforms, customer insights & feedback, customer relationship management, personalization & optimization, and employee experience. For more information, visit www.dashresearch.com or call +1.720.603.1700. Contact Details Clint Wheelock +1 720-603-1700 press@dashnetwork.com Company Website http://www.dashnetwork.com

November 15, 2021 05:30 AM Eastern Standard Time

Doseology Receives Receipt for Final Prospectus and Announces Listing on the CSE

Doseology Sciences Inc.

NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE UNITED STATES Doseology Sciences Inc. (“ Doseology ” or the “ Company ”), a diversified life sciences company, is pleased to announce that it has obtained a receipt for its final non-offering, long form prospectus dated October 29, 2021 from the British Columbia Securities Commission. Concurrent with its prospectus filing, the Company also received approval from the Canadian Securities Exchange (the “ CSE ”) to list the Company’s common shares on the CSE. The approval results in the Company’s previously issued 11,885,000 Subscription Receipts (aggregate gross proceeds of $2,377,000) to be automatically converted, without further payment, into 5,942,500 units. Each unit is comprised of one common share (a “ Share ”) and one common share purchase warrant (a “ Warrant ”) with each Warrant exercisable into one Share at a price of $0.80 per Share for a period of 24 months. The Company may elect, at its option, to accelerate the expiry date of the Warrants to a date that is 30 days from the date of notice to the Warrant holders if the closing price of the Shares on the CSE is equal to or greater than $1.40 for 20 consecutive trading days. The common shares of the Company will commence trading on the CSE on Monday, November 15, 2021 under the symbol “ MOOD ”. Daniel Vice, CEO of Doseology, commented “We are thrilled to finally obtain our listing on the CSE and are appreciative of the significant efforts of our team, our advisors, and the exchange to get to the finish line”. Mr. Vice further commented, “We now look forward to significantly accelerate the development of our ambitious business plan, through organic growth, partnerships, joint ventures and acquisitions“. No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board of Directors Doseology Sciences Inc. Daniel Vice Chief Executive Officer and Director ABOUT DOSEOLOGY (CSE: MOOD) Doseology is a BC-based company on a mission to restore mental health through establishing psychedelic-assisted therapy clinics, building a library of intellectual property through research on psychedelic compounds, and the development and sale of its branded functional mushroom products. The Company has filed an application with Health Canada to become a “Licensed Dealer” under the Controlled Drugs and Substances Act (Canada) which would permit the laboratory analysis of psilocybin and psilocin from mushrooms, as well as the possession, processing, sale, sending, transportation and delivery of Psychedelic Compounds. FOR FURTHER INFORMATION CONTACT: Investor Relations Email: investor@doseology.com Telephone: 236-349-0064 Website: www.doseology.com Forward Looking Statements This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Contact Details Investor Relations +1 236-349-0064 investor@doseology.com

November 12, 2021 06:21 PM Eastern Standard Time

1 ... 248 249 250 251 252 ... 306